Abstract
The clinical effects of a new quinolone drug, pazufloxacin (PZFX), were investigated in obstetric and gynecologic infections.
1) The drug was administered to 19 patients with obstetric and gynecologic infections at a dose of 100-200mg 2-3 times a day for 2-14 days, and the efficacy was evaluated in 12 of them (5 patients with indefinite symptoms, 1 patient who didn't visit after treatment and 1 patient in whom medication was discontinued due to side effects were excluded).
2) The clinical efficacy was good in all patients: endometritis, 5 patients; salpingitis, 4; Bartholin abscess, 2; perineal abscess, 1.
3) Bacteriologically, all of the 8 strains of 8 species detected in 6 patients were eradicated.
4) As a side effect, mild rash was observed in 1 patient. No abnormal findings were observed on clinical laboratory tests. These findings indicate that PZFX is useful in obstetric and gynecologic infections.
